跳至主要内容
临床试验/NCT04293133
NCT04293133Unknown不适用

Final Height in Patients With Congenital Adrenal Hyperplasia

Ain Shams University0 个研究点目标入组 30 人开始时间: 2020年3月11日最近更新:
适应症

试验速览

阶段
不适用
入组人数
30
主要终点
Final height in patients with congenital adrenal hyperplasia

研究概览

简要总结

Congenital adrenal hyperplasia (CAH) is the most common inherited disorder in the adrenal gland in children. Growth is usually affected in CAH patients either due to the disease itself or treatment consequences.

详细描述

CAH comprises a group of autosomal recessive disorders caused by a deficiency of one of five enzymes needed for the synthesis of cortisol leading to defect in cortisol synthesis with or without aldosterone deficiency and an increase in the production of adrenocorticotropic hormone through negative feedback.

The most common form is 21-hydroxylase deficiency (21OHD), which forms more than 90 % of the cases.

In classic CAH, 75% of the patients have the salt wasting (SW) and 25% have the non salt-wasting phenotype (NSW).There are no clinical signs at birth in male infants and in female patients, CAH is suspected shortly after birth if there is genital ambiguity, ranging from slight clitromegaly to complete masculinization with acceleration of growth and pubertal development.

The non-classic (late onset) form of CAH is a less severe form of 21OHD, and is diagnosed later in life.

Final height in early and late onset patients has been reported as diminished (Hauffa et al, 1997).This could be attributed to androgen excess or treatment with steroids. Androgen excess can occur at any age leading to accelerated growth, early epiphyseal closure and compromised final adult height.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
— 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Patients having a documented history of classical CAH.

排除标准

  • Patients with non classical CAH.
  • Patients treated with growth hormone.
  • Chronic use of medications unrelated to CAH which may affect growth like immunosuppressive drugs like azathioprine and drugs that affect growth hormone release like octreotide, pegvisomant, bromocriptine and cabergoline.
  • Other chronic diseases that may affect growth like heart disease, inflammatory bowel disease and renal disease.
  • Other causes of adrenal insufficiency.

结局指标

主要结局

Final height in patients with congenital adrenal hyperplasia

时间窗: Baseline

Target height(TH) will be calculated using the formula: \[maternal height + paternal height - 13 cm for girls and + 13 cm for boys\]/2

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mohammed Kamel El-Desouky Ashour

Final height in patients with congenital adrenal hyperplasia

Ain Shams University

相似试验